Single User License
INR 128980
Site License
INR 257960
Corporate User License
INR 386940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Follicular Thyroid Cancer-Pipeline Review, H2 2015

Follicular Thyroid Cancer-Pipeline Review, H2 2015


  • Products Id :- GMDHC6926IDB
  • |
  • Pages: 91
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Follicular Thyroid Cancer-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Follicular Thyroid Cancer-Pipeline Review, H2 2015', provides an overview of the Follicular Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Follicular Thyroid Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Follicular Thyroid Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Follicular Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Follicular Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Follicular Thyroid Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Follicular Thyroid Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Follicular Thyroid Cancer Overview 6

Therapeutics Development 7

Pipeline Products for Follicular Thyroid Cancer-Overview 7

Pipeline Products for Follicular Thyroid Cancer-Comparative Analysis 8

Follicular Thyroid Cancer-Therapeutics under Development by Companies 9

Follicular Thyroid Cancer-Therapeutics under Investigation by Universities/Institutes 10

Follicular Thyroid Cancer-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Follicular Thyroid Cancer-Products under Development by Companies 14

Follicular Thyroid Cancer-Products under Investigation by Universities/Institutes 15

Follicular Thyroid Cancer-Companies Involved in Therapeutics Development 16

AstraZeneca Plc 16

Eisai Co., Ltd. 17

Exelixis, Inc. 18

Novartis AG 19

Pfizer Inc. 20

Follicular Thyroid Cancer-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

cabozantinib s-malate-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

dabrafenib mesylate-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

everolimus-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

lenvatinib-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

pasireotide-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

sunitinib malate-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

tetraiodothyroacetic acid-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

vandetanib-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Follicular Thyroid Cancer-Recent Pipeline Updates 60

Follicular Thyroid Cancer-Dormant Projects 87

Follicular Thyroid Cancer-Product Development Milestones 88

Featured News & Press Releases 88

May 06, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains European Orphan Drug Status 88

Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 88

Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 88

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

Number of Products under Development for Follicular Thyroid Cancer, H2 2015 7

Number of Products under Development for Follicular Thyroid Cancer-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Products under Investigation by Universities/Institutes, H2 2015 15

Follicular Thyroid Cancer-Pipeline by AstraZeneca Plc, H2 2015 16

Follicular Thyroid Cancer-Pipeline by Eisai Co., Ltd., H2 2015 17

Follicular Thyroid Cancer-Pipeline by Exelixis, Inc., H2 2015 18

Follicular Thyroid Cancer-Pipeline by Novartis AG, H2 2015 19

Follicular Thyroid Cancer-Pipeline by Pfizer Inc., H2 2015 20

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Stage and Target, H2 2015 23

Number of Products by Stage and Mechanism of Action, H2 2015 25

Number of Products by Stage and Route of Administration, H2 2015 27

Number of Products by Stage and Molecule Type, H2 2015 29

Follicular Thyroid Cancer Therapeutics-Recent Pipeline Updates, H2 2015 60

Follicular Thyroid Cancer-Dormant Projects, H2 2015 87

List of Figures

Number of Products under Development for Follicular Thyroid Cancer, H2 2015 7

Number of Products under Development for Follicular Thyroid Cancer-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Late Stage Development, H2 2015 11

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Top 10 Targets, H2 2015 22

Number of Products by Stage and Top 10 Targets, H2 2015 22

Number of Products by Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Top 10 Routes of Administration, H2 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26

Number of Products by Top 10 Molecule Types, H2 2015 28

Number of Products by Stage and Top 10 Molecule Types, H2 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AstraZeneca Plc

Eisai Co., Ltd.

Exelixis, Inc.

Novartis AG

Pfizer Inc.

Follicular Thyroid Cancer Therapeutic Products under Development, Key Players in Follicular Thyroid Cancer Therapeutics, Follicular Thyroid Cancer Pipeline Overview, Follicular Thyroid Cancer Pipeline, Follicular Thyroid Cancer Pipeline Assessment


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com